
Revolution Medicines (RVMD) Stock Forecast & Price Target
Revolution Medicines (RVMD) Analyst Ratings
Bulls say
Revolution Medicines is viewed positively because RASONQUE’s first commercial quarter delivered about $198M in sales in 3Q26, far above both the ~$14M estimate and the $24.9M consensus, while treatment reached over 5,000 unique PDAC patients shortly after the August 26 FDA approval. The company’s strong cash position of roughly $3.72B, narrower 3Q26 net loss of $1.90 per share versus the expected $2.42, and R&D and SG&A that remained broadly manageable support financial durability and a runway into profitability. Its outlook is further strengthened by a differentiated RAS platform with broad pipeline optionality across PDAC, NSCLC, and CRC, including ongoing or planned late-stage trials and a pan-RAS mechanism that may support broad adoption and future growth.
Bears say
Revolution Medicines is viewed negatively because its valuation depends heavily on a small number of clinical-stage pipeline programs, leaving the company exposed to binary development risk. Setbacks in those programs, a regulatory review that takes longer than expected, or more modest commercial uptake could materially weaken the investment case and pressure the company’s long-term fundamentals. The downside scenario underscores that even if the science remains promising, delayed approval or softer adoption could limit value creation and keep shares vulnerable to substantial downside.
This aggregate rating is based on analysts' research of Revolution Medicines and is not a guaranteed prediction by Public.com or investment advice.
Revolution Medicines (RVMD) Analyst Forecast & Price Prediction
Start investing in Revolution Medicines (RVMD)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Revolution Medicines (RVMD) Forecast
Revolution Medicines (RVMD) Analyst Forecast & Price Prediction
Start investing in Revolution Medicines (RVMD)
Order type
Buy in
Order amount
Est. shares
0 shares